Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count

Post Date: 
2011-03-27
   |      |   
Clinical Sites: 
Publication: 
AIDS Care
Summary: 
Objectives: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via breastfeeding and mortality. We now present endpoints through 12 months of age.
 
Design: Infants in Ethiopia, India, and Uganda born to HIV-infected women who chose to breastfeed were randomized to receive single-dose or extended-dose nevirapine.
Citation: 
Omer S, for the Six Week Extended Dose Nevirapine (SWEN) Study Team. Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS Care. 2011 Mar 27; 25:767-776.
Collaborators: 
  • Addis Ababa University, Addis Ababa, Ethiopia
  • BJGMC, Pune, India
  • ICMR/National AIDS Research Institute, Pune, India
  • Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
  • NIH/NIAID, Bethesda, MD